Florida Hospital DeLand is one of three hospitals in the state testing an experimental anti-venom for coral snake bites. The brightly colored snake rarely bites, but just a drop of its venom is a lethal dose.
The costs of prescription drugs have grown more quickly than any other part of the healthcare industry, and a new report estimates a small portion of breakthrough specialty drugs will further strain the budgets of federal and state healthcare programs.
The federal government is launching a very different kind of cancer study that will assign patients drugs based on what genes drive their tumors rather than the type.
A strong sales year for its prescription products and participation in emerging markets enabled Novartis Corp. to maintain its position as the largest pharmaceutical company in 2014. Meanwhile, Actavis saw a 50.5% revenue increase, and Biogen's revenue grew by 40%.
Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Pfizer, Merck & Co. and Bristol-Myers Squibb Co., which reported first-quarter results Tuesday, all derive at least half their...
For women who aspire to healthcare's executive-level roles, advanced education and the willingness to take risks may not be enough. Surveys of corporate leadership and healthcare management point to a continued, though narrowing, disparity of women to men in leadership roles.
Pfizer is buying Hospira for approximately $15.23 billion, saying it is a good fit with its global established pharmaceutical business.
The Institute of Medicine released four recommendations to address practices that often have left relevant medical research unpublished and useful data unattainable by independent researchers.
Baxter International is selling its vaccine business to Pfizer for $635 million as it prepares to split into two companies.
Pfizer's second-quarter earnings plunged 79% from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.
The rumblings that corporate tax reform will close favorable loopholes for pharmaceutical and biotechnology companies are getting louder, fueling a rush of high-dollar cross-border deals.
With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from Pfizer to create the world's largest pharmaceutical company.